DISCLAIMER No information set out or referred to in this fall as well as rise. In particular, investments The information contained in this research research report shall form the basis of any in the technology sector can involve a high degree report or any copy of part thereof should not be contract. The issue of this research report shall of risk and investors may not get back the full accessed by a person in any jurisdictions where not be deemed to be any form of binding offer amount invested. its access may be restricted by law and persons or commitment on the part of GP Bullhound into whose possession the information in this LLP. This research report is provided for use by The information contained in this research research report comes should inform themselves the intended recipient for information purposes report is based on materials and sources that about, and observe, any such restrictions. Access only. It is prepared on the basis that the recipients are believed to be reliable; however, they have of the information contained in this research are sophisticated investors with a high degree of not been independently verified and are not report in any such jurisdictions may constitute financial sophistication and knowledge. This guaranteed as being accurate. The information a violation of UK or US securities law, or the research report and any of its information is not contained in this research report is not intended law of any such other jurisdictions. Neither the intended for use by private or retail investors in to be a complete statement or summary of any whole nor any part of the information contained the UK or any other jurisdiction. securities, markets, reports or developments in this research report may be duplicated in referred to herein. No representation or any form or by any means. Neither should the You, as the recipient of this research report, warranty, either express or implied, is made or information contained in this research report, acknowledge and agree that no person has nor accepted by GP Bullhound LLP, its members, or any part thereof, be redistributed or disclosed is held out as having any authority to give directors, officers, employees, agents or associated to anyone without the prior consent of GP any statement, warranty, representation, or undertakings in relation to the accuracy, Bullhound LLP. undertaking on behalf of GP Bullhound LLP completeness or reliability of the information in connection with the contents of this research in this research report nor should it be relied GP Bullhound LLP and/or its associated report. Although the information contained in upon as such. This research report may contain undertakings may from time-to-time provide this research report has been prepared in good forward-looking statements, which involve investment advice or other services to, or solicit faith, no representation or warranty, express or risks and uncertainties. Forward-looking such business from, any of the companies implied, is or will be made and no responsibility information is provided for illustrative purposes referred to in the information contained in this or liability is or will be accepted by GP only and is not intended to serve as, and must research report. Accordingly, information may Bullhound LLP. In particular, but without not be relied upon as a guarantee, an assurance, be available to GP Bullhound LLP that is not prejudice to the generality of the foregoing, no a prediction or a definitive statement of fact or reflected in this material and GP Bullhound representation or warranty is given as to the probability. Actual events and circumstances are LLP may have acted upon or used the accuracy, completeness or reasonableness of difficult or impossible to predict and may differ information prior to or immediately following any projections, targets, estimates or forecasts from assumptions. its publication. In addition, GP Bullhound contained in this research report or in such other LLP, the members, directors, officers and/or written or oral information that may be provided Any and all opinions expressed are current employees thereof and/or any connected persons by GP Bullhound LLP. The information in opinions as of the date appearing on the may have an interest in the securities, warrants, this research report may be subject to change at documents included in this research report. futures, options, derivatives or other financial any time without notice. GP Bullhound LLP Any and all opinions expressed are subject to instrument of any of the companies referred to is under no obligation to provide you with change without notice and GP Bullhound LLP in this research report and may from time-to- any such updated information. All liability is is under no obligation to update the information time add or dispose of such interests. expressly excluded to the fullest extent permitted contained in this research report. by law. Without prejudice to the generality of GP Bullhound LLP is a limited liability the foregoing, no party shall have any claim for The information contained in this research partnership registered in England and Wales, innocent or negligent misrepresentation based report should not be relied upon as being an registered number OC352636, and is authorised upon any statement in this research report or indepe ndent or impartial view of the subject and regulated by the Financial Conduct any representation made in relation thereto. matter and for the purposes of the rules and Authority. Any reference to a partner in relation Liability (if it would otherwise but for this guidance of the Financial Conduct Authority to GP Bullhound LLP is to a member of GP paragraph have arisen) for death or personal (“the FCA”) this research report is a marketing Bullhound LLP or an employee with equivalent injury caused by the negligence (as defined in communication and a financial promotion. standing and qualifications. A list of the Section 1 of the Unfair Contracts Terms Act Accordingly, its contents have not been prepared members of GP Bullhound LLP is available 1977) of GP Bullhound LLP, or any of its in accordance with legal requirements designed to for inspection at its registered office, 52 Jermyn respective affiliates, agents or employees, is not promote the independence of investment research Street, London SW1Y 6LX. hereby excluded nor is damage caused by their and it is not subject to any prohibition on fraud or fraudulent misrepresentation. dealing ahead of the dissemination of investment GP Bullhound Sidecar III LP is an investor research. The individuals who prepared the in Spotify. This research report should not be construed information contained in this research report in any circumstances as an offer to sell or may be involved in providing other financial For US Persons: This research report is solicitation of any offer to buy any security or services to the company or companies reference d distributed to US persons by GP Bullhound other financial instrument, nor shall they, or in this research report or to other companies who Inc. a broker-dealer registered with the SEC the fact of the distribution, form the basis of, or might be said to be competitors of the company and a member of the FINRA. GP Bullhound be relied upon in connection with, any contract or companies referenced in this research report. Inc. is an affiliate of GP Bullhound LLP. This relating to such action. The information As a result, both GP Bullhound LLP and the research report does not provide personalized contained in this research report has no regard individual members, directors, officers and/ advice or recommendations of any kind. All for the specific investment objectives, financial or employees who prepared the information investments bear certain material risks that situation or needs of any specific entity and contained in this research report may have should be considered in consultation with an is not a personal recommendation to anyone. responsibilities that conflict with the interests investors financial, legal and tax advisors. GP Persons reading this research report should make of the persons who access this research report. Bullhound Inc. engages in private placement their own investment decisions based upon their GP Bullhound LLP and/or connected persons and mergers and acquisitions advisory activities own financial objectives and financial resources may, from time to time, have positions in, make with clients and counterparties in the Technology and, if in any doubt, should seek advice from a market in and/or effect transactions in any and CleanTech sectors. an investment advisor. Past performance of investment or related investment mentioned in securities is not necessarily a guide to future this research report and may provide financial performance and the value of securities may services to the issuers of such investments.